PharmAla Biotech Signs $100 Million-Plus Term Sheet to License ALA-002 MDMA Therapeutic to Jupiter Neurosciences

PharmAla Biotech has signed a term sheet granting Jupiter Neurosciences, Inc. (NASDAQ: JUNS) exclusive U.S. licensing rights to ALA-002, its next-generation MDMA therapeutic, in a transaction valued at over $100 million. The agreement positions the Nasdaq-listed Jupiter Neurosciences as PharmAla's designated U.S. partner for the MDMA-based drug candidate. At over $100 million, the deal's stated valuation signals the commercial weight both parties are assigning to ALA-002's prospects in the American market.

ALA-002: PharmAla's Next-Generation MDMA Therapeutic

ALA-002 is PharmAla Biotech's next-generation MDMA therapeutic and the compound at the center of the Jupiter Neurosciences arrangement. The term sheet covers exclusive U.S. rights to the asset, with the United States defined as the geographic scope of what Jupiter Neurosciences is acquiring. The over $100 million valuation applies specifically to this U.S.-bounded license, making the American market the full extent of Jupiter Neurosciences' claim to ALA-002 under the proposed deal.

Jupiter Neurosciences (JUNS): The Named Licensee

Jupiter Neurosciences, Inc. trades on the Nasdaq under the ticker JUNS and is the counterparty taking on the ALA-002 U.S. license from PharmAla Biotech. The structure is a licensing arrangement — granting JUNS exclusive U.S. rights to an MDMA-based therapeutic candidate — rather than an outright acquisition of the underlying asset or of PharmAla Biotech itself. The over $100 million figure attaches to that licensing right alone.

Term Sheet Stage: The Path to a Binding Agreement

The signed document is a term sheet, which sets out the proposed key terms of the transaction before the parties execute a definitive, binding agreement. The over $100 million ALA-002 U.S. licensing deal between PharmAla Biotech and Jupiter Neurosciences therefore remains subject to the negotiation and execution of final contracts. The disclosed term sheet nonetheless constitutes a formal, public commitment by both companies to advance the transaction toward completion.